+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Fallopian Tube Cancer Therapeutics Market 2019-2023 - Product Image

Global Fallopian Tube Cancer Therapeutics Market 2019-2023

  • ID: 4825184
  • Report
  • Region: Global
  • 136 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • MORE
Global Fallopian Tube Cancer Therapeutics Market: About this market

Fallopian tube cancer is a less common type of gynecologic cancer and accounts for approximately 1%-2% of all gynecologic cancer cases. The fallopian tube cancer therapeutics market analysis considers sales from both targeted therapy and chemotherapy. Our analysis also considers the sales of fallopian tube cancer therapeutics in APAC, Europe, North America, South America, and MEA. In 2018, the targeted therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as heavy research on targeted therapies, high efficacy of the same will play a significant role in the targeted therapy segment to maintain its market position. Also, our global fallopian tube cancer therapeutics market report also looks at factors such as growing attention toward women's health, an array of strong drug approvals, strategic alliance. However, difficulty in diagnosis, the strong threat from substitutes, high cost of treatment may hamper the growth of the fallopian tube cancer therapeutics industry over the forecast period.

Global Fallopian Tube Cancer Therapeutics Market: Overview

Array of strong drug approvals

One of the major growth factors of the global fallopian tube cancer therapeutics market is the increasing number of drug approvals in recent years. Various pharmaceutical vendors started conducting research on novel targeted therapies. These targeted therapies have an affinity toward inhibiting the overexpression of a specific target and increasing the immunity of the body toward cancerous cells. The market also witnesses the presence of various other targeted therapies in the late stages of the pipeline for the treatment of fallopian tube cancer. Two of the heavily researched targeted therapies for the indication are PD-1 inhibitors and PD-L1 inhibitors. The studies conducted in the early stages of clinical trials for fallopian tube cancer suggest that these drugs show a significant reduction in the tumor while providing long-term relief. Such factors will lead to the expansion of the global fallopian tube cancer therapeutics market at a CAGR of over 8% during the forecast period.

Use of nanotechnology for effective treatment

Various researchers are conducting studies on developing a nanoparticle-based drug delivery system, which could help the drug in reaching the target site without reducing its bioavailability. They increase the half-life of the drug in the circulatory system and have the ability to bypass the barriers caused by the blood tissue, specific target tissues, and cells. They increase the onset of the drug while providing a prolonged therapeutic action. These factors help nanoparticles to be an effective drug delivery for the administration of chemotherapy drugs. as it helps in overcoming drug resistance mechanisms in various tumors while enhancing the drug penetration into the tumor. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of a few major players, the global fallopian tube cancer therapeutics market is concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading fallopian tube cancer therapeutics manufacturers, that include AstraZeneca Plc, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, and Pfizer Inc.

Also, the fallopian tube cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Targeted therapy - Market size and forecast 2018-2023
  • Chemotherapy - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Growing research on regenerative therapies
  • Advent of treatment vaccines for cancer
  • Use of nanotechnology for effective treatment
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Global fallopian tube cancer therapeutics market: Overview
Exhibit 19: Global fallopian tube cancer therapeutics market: Snapshot
Exhibit 20: Product - Market share 2018-2023 (%)
Exhibit 21: Comparison by product
Exhibit 22: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: VEGF inhibitors share in targeted therapy 2018-2023
Exhibit 24: PARP inhibitors share in targeted therapy 2018-2023
Exhibit 25: Other inhibitors share in targeted therapy 2018-2023
Exhibit 26: Targeted therapy - Year-over-year growth 2019-2023 (%)
Exhibit 27: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in North America
Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Europe
Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in Asia
Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 43: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in ROW
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: AstraZeneca Plc - Vendor overview
Exhibit 54: AstraZeneca Plc - Business segments
Exhibit 55: AstraZeneca Plc - Organizational developments
Exhibit 56: AstraZeneca Plc - Geographic focus
Exhibit 57: AstraZeneca Plc - Key offerings
Exhibit 58: AstraZeneca Plc - Key customers
Exhibit 59: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 60: Bristol-Myers Squibb Co. - Business segments
Exhibit 61: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 62: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 63: Bristol-Myers Squibb Co. - Key offerings
Exhibit 64: Bristol-Myers Squibb Co. - Key customers
Exhibit 65: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 66: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 67: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 68: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 69: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 70: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 71: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 72: GlaxoSmithKline Plc - Vendor overview
Exhibit 73: GlaxoSmithKline Plc - Business segments
Exhibit 74: GlaxoSmithKline Plc - Organizational developments
Exhibit 75: GlaxoSmithKline Plc - Geographic focus
Exhibit 76: GlaxoSmithKline Plc - Segment focus
Exhibit 77: GlaxoSmithKline Plc - Key offerings
Exhibit 78: GlaxoSmithKline Plc - Key customers
Exhibit 79: Pfizer Inc. - Vendor overview
Exhibit 80: Pfizer Inc. - Business segments
Exhibit 81: Pfizer Inc. - Organizational developments
Exhibit 82: Pfizer Inc. - Geographic focus
Exhibit 83: Pfizer Inc. - Segment focus
Exhibit 84: Pfizer Inc. - Key offerings
Exhibit 85: Pfizer Inc. - Key customers
Exhibit 86: Validation techniques employed for market sizing
Exhibit 87: Definition of market positioning of vendors


Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global automotive steering lock system market: AstraZeneca Plc, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, and Pfizer Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the use of nanotechnology for effective treatment.”

According to the report, one of the major drivers for this market is the array of strong drug approvals.

Further, the report states that one of the major factors hindering the growth of this market is the high cost of treatment.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll